These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2674359)

  • 1. Modulation of glycolysis in neuroepithelial tumors.
    Floridi A; Paggi MG; Fanciulli M
    J Neurosurg Sci; 1989; 33(1):55-64. PubMed ID: 2674359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lonidamine on the utilization of 14C-labeled glucose by human astrocytoma cells.
    Paggi MG; Zupi G; Fanciulli M; Del Carlo C; Giorno S; Laudonio N; Silvestrini B; Caputo A; Floridi A
    Exp Mol Pathol; 1987 Oct; 47(2):154-65. PubMed ID: 2820786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lonidamine on human malignant gliomas: biochemical studies.
    Paggi MG; Carapella CM; Fanciulli M; Del Carlo C; Giorno S; Zupi G; Silvestrini B; Caputo A; Floridi A
    J Neurooncol; 1988 Nov; 6(3):203-9. PubMed ID: 3225640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.
    Floridi A; Paggi MG; Marcante ML; Silvestrini B; Caputo A; De Martino C
    J Natl Cancer Inst; 1981 Mar; 66(3):497-9. PubMed ID: 6937706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeting the gene of glucose metabolism for the treatment of advanced gliomas].
    Oudard S; Miccoli L; Dutrillaux B; Poupon MF
    Bull Cancer; 1998 Jul; 85(7):622-6. PubMed ID: 9752269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
    Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
    Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of aerobic glycolysis in normal and neoplastic lymphoid cells induced by Lonidamine [1-(2,4-dichlorobenzyl)-I-H-indazol-3-carboxylic acid].
    Natali PG; Salsano F; Viora M; Nista A; Malorni W; Marolla A; De Martino C
    Oncology; 1984; 41 Suppl 1():7-14. PubMed ID: 6609324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure.
    Oudard S; Boitier E; Miccoli L; Rousset S; Dutrillaux B; Poupon MF
    Anticancer Res; 1997; 17(3C):1903-11. PubMed ID: 9216643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy.
    Kalia VK; Prabhakara S; Narayanan V
    J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S57-60. PubMed ID: 20009297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.
    Ben-Yoseph O; Lyons JC; Song CW; Ross BD
    J Neurooncol; 1998 Jan; 36(2):149-57. PubMed ID: 9525814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lonidamine on protein synthesis in neoplastic cells.
    Floridi A; Delpino A; Nista A; Feriozzi R; Marcante ML; Silvestrini B; Caputo A
    Exp Mol Pathol; 1985 Jun; 42(3):293-305. PubMed ID: 3996552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lonidamine on the aerobic glycolysis of normal and phytohemagglutinin-stimulated human peripheral blood lymphocytes.
    Nista A; De Martino C; Malorni W; Marcante ML; Silvestrini B; Floridi A
    Exp Mol Pathol; 1985 Apr; 42(2):194-205. PubMed ID: 3156759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondria-bound hexokinase as target for therapy of malignant gliomas.
    Oudard S; Poirson F; Miccoli L; Bourgeois Y; Vassault A; Poisson M; Magdelénat H; Dutrillaux B; Poupon MF
    Int J Cancer; 1995 Jul; 62(2):216-22. PubMed ID: 7622299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies.
    Ben-Horin H; Tassini M; Vivi A; Navon G; Kaplan O
    Cancer Res; 1995 Jul; 55(13):2814-21. PubMed ID: 7796408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lonidamine in the combined treatment of malignant gliomas. A randomized study.
    Carapella CM; Paggi MG; Calvosa F; Cattani F; Jandolo B; Mastrostefano R; Raus L; Riccio A
    J Neurosurg Sci; 1990; 34(3-4):261-4. PubMed ID: 2098504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mitochondrial hexokinase in neoplastic phenotype and its sensitivity to lonidamine.
    Paggi MG; Fanciulli M; Perrotti N; Floridi A; Zeuli M; Silvestrini B; Caputo A
    Ann N Y Acad Sci; 1988; 551():358-60. PubMed ID: 3245672
    [No Abstract]   [Full Text] [Related]  

  • 17. The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.
    Carapella CM; Paggi MG; Cattani F; Ciottoli GB; Floridi A; Iandolo B; Raus L; Riccio A; Caputo A
    J Neurooncol; 1989 May; 7(1):103-8. PubMed ID: 2666593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lonidamine-induced, pH dependent inhibition of cellular oxygen utilization.
    Stryker JA; Gerweck LE
    Radiat Res; 1988 Feb; 113(2):356-61. PubMed ID: 3340739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lonidamine in malignant brain tumors.
    Schiffer D; Sales S; Soffietti R
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):38-41. PubMed ID: 2031197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological effects of lonidamine on two human-tumor cell culture lines.
    Szekely JG; Lobreau AU; Delaney S; Raaphorst GP; Feeley M
    Scanning Microsc; 1989 Jun; 3(2):681-91; discussion 691-3. PubMed ID: 2814409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.